United Therapeutics Corporation (UTHR)vsViatris Inc (VTRS)
UTHR
United Therapeutics Corporation
$524.28
-0.52%
HEALTHCARE · Cap: $23.67B
VTRS
Viatris Inc
$13.20
-2.22%
HEALTHCARE · Cap: $15.56B
Smart Verdict
WallStSmart Research — data-driven comparison
Viatris Inc generates 349% more annual revenue ($14.30B vs $3.18B). UTHR leads profitability with a 41.9% profit margin vs -24.6%. VTRS appears more attractively valued with a PEG of 0.07. UTHR earns a higher WallStSmart Score of 67/100 (B-).
UTHR
Strong Buy67
out of 100
Grade: B-
VTRS
Buy50
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+63.2%
Fair Value
$1294.44
Current Price
$524.28
$770.16 discount
Intrinsic value data unavailable for VTRS.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 42 of every $100 in revenue as profit
Strong operational efficiency at 45.0%
Safe zone — low bankruptcy risk
Earnings expanding 24.5% YoY
Growing faster than its price suggests
Reasonable price relative to book value
Areas to Watch
Expensive relative to growth rate
ROE of -21.1% — below average capital efficiency
Earnings declined 70.6%
Distress zone — elevated risk
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : UTHR
The strongest argument for UTHR centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 41.9% and operating margin at 45.0%.
Bull Case : VTRS
The strongest argument for VTRS centers on PEG Ratio, Price/Book. PEG of 0.07 suggests the stock is reasonably priced for its growth.
Bear Case : UTHR
The primary concerns for UTHR are PEG Ratio.
Bear Case : VTRS
The primary concerns for VTRS are Return on Equity, EPS Growth, Altman Z-Score.
Key Dynamics to Monitor
UTHR profiles as a mature stock while VTRS is a turnaround play — different risk/reward profiles.
UTHR carries more volatility with a beta of 0.86 — expect wider price swings.
UTHR is growing revenue faster at 7.4% — sustainability is the question.
VTRS generates stronger free cash flow (551M), providing more financial flexibility.
Bottom Line
UTHR scores higher overall (67/100 vs 50/100), backed by strong 41.9% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
United Therapeutics Corporation
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
United Therapeutics Corporation, a biotechnology company, is dedicated to the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company is headquartered in Silver Spring, Maryland.
Visit Website →Viatris Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?